Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Posts 26 Percent Rise in Q3 Revenues

NEW YORK (GenomeWeb News) – NeoGenomics today reported third-quarter revenue growth of 26 percent year over year.

For the three months ended Sept. 30, the Ft. Meyers, Fla.-based cancer genetic testing firm said that revenues rose to $14.2 million from $11.3 million a year ago. The number of tests performed in the quarter increased to 28,315 from 19,977, but the average revenue per test dipped to $501.58 from $566.66.

The decrease resulted from the expiration of the Medicare Technical Component Grandfather Clause on June 30, leading to an estimated reduction in revenue of $1.3 million, NeoGenomics said.

Its R&D spending spiked to $808,000 from $125,000 a year ago, and SG&A costs of $5.8 million represented an 18 percent increase from $4.9 million for the third quarter a year ago.

NeoGenomics' net loss widened to $975,000, or $.02 per share, in the quarter from a net loss of $143,000, or break-even, a year ago.

NeoGenomics finished the quarter with $2.0 million in cash and cash equivalents, and $300,000 in restricted cash.

For the fourth quarter, the company forecast revenue of between $14.3 million and $15.0 million and per-share figures of between break-even and a net loss of $.01. Full-year revenue estimates were narrowed to a range of $59 million to $60 million from an earlier range of $57 million to $63 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.